Evolus, Inc. (EOLS): Total Liabilities
$248.97M
As of 2025-12-31
$278.93M
As of 2026-06-30
+16.0%
3-year compound annual growth
-2.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $248.97M | +9.7% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $227.05M | +8.3% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $209.69M | +31.5% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $159.48M | -9.2% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $175.61M | -37.7% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $282.03M | +75.2% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $160.99M | +84.1% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $87.46M | -61.6% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $227.78M | n/a | 2019-03-20, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 2025-12-31 | $248.97M | +9.7% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $420.83M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $509.73M | +128.3% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $543.42M | +388.1% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $284.00M | -46.4% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $362.11M | -9.9% |
| MannKind Corp (MNKD) | 2025-12-31 | $843.20M | +78.4% |
Compare EOLS, XERS, CRMD, HROW side by side · Screen every company in Pharmaceutical Preparations ↗